Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis

详细信息    查看全文

• 作者：Shichao Li ; Xiaorong Yang ; Jinmei Yang ; Jiesheng Zhen…
• 关键词：Breast cancer ; miR ; 21 ; Diagnosis ; Meta ; analysis
• 刊名：Clinical and Experimental Medicine
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：16
• 期：1
• 页码：29-35
• 全文大小：998 KB
• 参考文献：1.DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71. doi:10.​3322/​caac.​21235 .CrossRef PubMed
  2.Danny RY, Susanna MC, Cheng HY, Baade PD, et al. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11:101–15. doi:10.​7497/​j.​issn.​2095-3941.​2014.​02.​005 .
  3.James SL, Water HG, Noel JW. Viruses and human breast cancer. Future microbiol. 2006;1(1):33–51.CrossRef
  4.Ismail J, John RB. Novel approaches to the diagnosis and treatment of breast cancer. Future Oncol. 2014;10(4):515–8.CrossRef
  5.Heywang-Kobrunner SH, Hacher A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care. 2011;6:199–207. doi:10.​1159/​000329005 .PubMedCentral CrossRef PubMed
  6.Euler-Chelpin MV, Louise MR, Brian LT, et al. Risk of breast cancer after false-positive test results in screening mammography. J Natl Cancer Inst. 2012;104(9):682–9. doi:10.​1093/​jnci/​djs176 .CrossRef
  7.Mahendar P, Nagulu M, Uday KV, et al. evaluation of tumor markers in southern Indian breast cancer patients. Asian Pac J Cancer Prev. 2010;11:157–9.
  8.Fiorella G, Patrizia F, Sandro C, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer : a prospective longitudinal study. Clin Cancer Res. 2001;7:2357–62.
  9.Nicolini A, Colombini C, Luciani L, et al. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991;64:154–8.PubMedCentral CrossRef PubMed
  10.Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345–51. doi:10.​1373/​clinchem.​2005.​059832 .CrossRef PubMed
  11.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi:10.​1016/​j.​cell.​2009.​01.​002 .PubMedCentral CrossRef PubMed
  12.Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–9. doi:10.​4161/​rna.​20378 .CrossRef PubMed
  13.Zhang J, Zhao H, Gao Y, et al. Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta. 2012;1826(1):32–43. doi:10.​1016/​j.​bbcan.​2012.​03.​001 .PubMed
  14.Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013;329(2):125–36. doi:10.​1016/​j.​canlet.​2012.​11.​001 .PubMedCentral CrossRef PubMed
  15.Heneghan HM, Miller N, Lowery AJ, et al. Circulating micrornas as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505. doi:10.​1097/​SLA.​0b013e3181cc939f​ .CrossRef PubMed
  16.Patrick SM, Rachael KP, Evan MK, et al. Circulating microRNAs as stable blood-basedmarkers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8. doi:10.​1073/​pnas.​0804549105 .CrossRef
  17.Li T, Leong MH, Harms B, et al. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol. 2013;19(34):5615–21. doi:10.​3748/​wjg.​v19.​i34.​5615 .PubMedCentral CrossRef PubMed
  18.Yang XR, Du Gao YN, et al. Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis. PloS One. 2013;9(5):e97460. doi:10.​1371/​journal.​pone.​0097460 eCollection 2014.CrossRef
  19.Zeng ZY, Wang JG, Zhao LY, et al. Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One. 2013;8(9):e73278. doi:10.​1371/​journal.​pone.​0073278 .PubMedCentral CrossRef PubMed
  20.Si HY, Sun XM, Chen YJ, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013;139(2):223–9. doi:10.​1007/​s00432-012-1315-y .PubMedCentral CrossRef PubMed
  21.Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93. doi:10.​1016/​j.​ygyno.​2010.​07.​021 .CrossRef PubMed
  22.Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91. doi:10.​1373/​clinchem.​2010.​151845 .CrossRef PubMed
  23.Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013;25(6):743–8. doi:10.​3978/​j.​issn.​1000-9604.​2013.​12.​04 .PubMedCentral PubMed
  24. Sun Y. Novel serum biomarkers in breast cancer : detection and clinical significance [Master]: National Center for Clinical Laboratory. 2012.
  25.Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138(10):1659–66. doi:10.​1007/​s00432-012-1244-9 .CrossRef PubMed
  26. Penny W, Anne WR, Johannes BR, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3(25).
  27.Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6(31). doi:10.​1186/​1471-2288-6-31 .
  28.Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Marker. 2013;34(3):163–9. doi:10.​3233/​dma-120957 .CrossRef
  29.Li XF, Xu JJ, Zhang QY. Establishment of real-time PCR for detecting serum micriRNA-21 and its preliminary application in breast cancer. Chin J Lab Med. 2011;34(10):920–5.
  30.Götte M. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol. 2010;62(6):559–71.PubMed
  31.Rahul S, Berna SS, Alex HM, et al. MicroRNA control of invasion and metastasis pathways. Front Genet. 2011;2:1–5. doi:10.​3389/​fgene.​2011.​00058 .
  32.Marilena V, Iorio PC, Piovan C, Braccioli L, Tagliabue E. Breast cancer and microRNAs: therapeutic impact. Breast. 2011;20(S3):S63–70. doi:10.​1016/​S0960-9776(11)70297-1 .
  33.Aoife JL, Nicola M, Roisin EM, et al. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin cancer Res. 2008;14:360–5. doi:10.​1158/​1078-0432.​CCR-07-0992 .CrossRef
  34.Cathy AA, Brian MN, Thompson EA, et al. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Cell. 2011;17(6):313–9. doi:10.​1016/​j.​molmed.​2011.​01.​006 .
  35.Afina S, Jeroen GL, Martin HP, Bossuyt PM, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35. doi:10.​1016/​S0895-4356(03)00177-X .CrossRef
  36.Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56. doi:10.​1002/​sim.​1099 .CrossRef PubMed
  
• 作者单位：Shichao Li (1)
  Xiaorong Yang (1)
  Jinmei Yang (1)
  Jiesheng Zhen (2)
  Dechun Zhang (1)
  
  1. Department of Pathogenic Biology, Molecular Oncology Laboratory, Chongqing Medical University, Chongqing, People’s Republic of China
  2. Clinical Laboratory, Renmin Hospital of WuHan University, Wuhan, Hubei, People’s Republic of China
  
• 刊物主题：Internal Medicine; Hematology; Oncology;
• 出版者：Springer Milan
• ISSN：1591-9528

文摘

Serum microRNA-21 (miR-21) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a biomarker to discriminate breast cancer patients from healthy controls. We therefore performed this meta-analysis to assess the diagnostic value of miR-21 for breast cancer. Relevant articles were collected from PubMed, Scopus, Embase, the Cochrane Library, BioMed Central, ISI Web of Knowledge, China National Knowledge Infrastructure, Wan Fang Data and Technology of Chongqing databases, from inception to June 10, 2014 by two independent researchers. Diagnostic capacity of miR-21 for breast cancer was assessed using pooled sensitivity and specificity, diagnostic odds ratio (DOR), area under the summary receiver operating characteristic (AUC) and Fagan’s nomogram. Meta-Disc software and Stata SE 12.0 were used to investigate the source of heterogeneity and to perform the meta-analysis. We used six studies with a total of 438 patients and 228 healthy controls in this meta-analysis. The pooled sensitivity, specificity and DOR were 0.79 [95 % confidence interval (CI) 0.66–0.87], 0.85 (95 % CI 0.75–0.91) and 19.46 (95 % CI 8.74–43.30), respectively; positive and negative likelihood ratios were 5 and 0.25, and AUC was 0.89 (95 % CI 0.86–0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. This meta-analysis suggests that miR-21 is a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and its clinical application warrants further investigation. Keywords Breast cancer miR-21 Diagnosis Meta-analysis